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Risk scoresAccurately identifying the patients that have mild cognitive impairment (MCI) who will go on to develop
Alzheimer's disease (AD) will become essential as new treatments will require identiﬁcation of AD patients
at earlier stages in the disease process. Most previous work in this area has centred around the same auto-
mated techniques used to diagnose AD patients from healthy controls, by coupling high dimensional brain
image data or other relevant biomarker data to modern machine learning techniques. Such studies can
now distinguish between AD patients and controls as accurately as an experienced clinician. Models trained
on patients with AD and control subjects can also distinguish between MCI patients that will convert to AD
within a given timeframe (MCI-c) and those that remain stable (MCI-s), although differences between
these groups are smaller and thus, the corresponding accuracy is lower. The most common type of classiﬁer
used in these studies is the support vector machine, which gives categorical class decisions. In this paper, we
introduce Gaussian process (GP) classiﬁcation to the problem. This fully Bayesian method produces naturally
probabilistic predictions, which we show correlate well with the actual chances of converting to AD within
3 years in a population of 96 MCI-s and 47 MCI-c subjects. Furthermore, we show that GPs can integrate mul-
timodal data (in this study volumetric MRI, FDG-PET, cerebrospinal ﬂuid, and APOE genotype with the clas-
siﬁcation process through the use of a mixed kernel). The GP approach aids combination of different data
sources by learning parameters automatically from training data via type-II maximum likelihood, which
we compare to a more conventional method based on cross validation and an SVM classiﬁer. When the
resulting probabilities from the GP are dichotomised to produce a binary classiﬁcation, the results for
predicting MCI conversion based on the combination of all three types of data show a balanced accuracy of
74%. This is a substantially higher accuracy than could be obtained using any individual modality or using a
multikernel SVM, and is competitive with the highest accuracy yet achieved for predicting conversion within
three years on the widely used ADNI dataset.
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The most common form of dementia in the elderly population is
Alzheimer's disease (AD), with prevalence expected to increase
greatly in coming years largely due to ageing and expected improve-
ments in care (Ferri et al., 2005). AD is a progressive condition initial-
ly associated with impairment of episodic memory, followed by other
cognitive domains, leading to increasing dependence and ultimately
to death. While familial AD is entirely genetic in aetiology, it consti-
tutes only a small minority (1–2%) of all cases. The more prevalent
sporadic form of AD has far more complex causes. While lifestyle
and genetic risk factors are signiﬁcant, ageing remains by far the
greatest risk factor. Current treatments for AD are palliative in nature,
relieving the symptoms to some degree without tackling the underly-
ing causes of the disease. As such, they cannot halt or even slow down
the disease process. However newer treatments are intended toserved.
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thought to be one of the underlying causes of AD (Robert and Wark,
2012). While these hold great promise, to be effective treatment
must begin in a much earlier stage in the disease process than current
treatments. As a result, there needs to be a shift in focus from diagno-
sis to prognosis of AD in patients showing very mild symptoms, and
eventually to people with no symptoms at all. Previous work has fo-
cused on studying patients with mild cognitive impairment (MCI)
(Petersen et al., 1999). MCI is typically deﬁned as a state where pa-
tients have isolated memory deﬁcits that are not severe enough to
affect normal living. Studies have shown that MCI patients convert
to AD at an annual rate of 10–15% per year (Braak and Braak, 1995).
MCI patients who do not convert to AD either develop other forms
of dementia, remain stable, or in a small minority, revert to a
nondemented state. Therefore predicting which MCI patients will de-
velop AD in the short term (i.e. within a few years) and which will re-
main stable is extremely relevant to future treatments. Although a
deﬁnitive diagnosis of AD can be made only at autopsy, in practice ex-
pert clinicians diagnose AD based on clinical history and batteries of
cognitive tests. However these standard clinical tests are not able to
identify the more subtle patterns of the disease process at this early
stage, so more advanced methods are required.
The automated methods used to discriminate between stable
(MCI-s) and converter (MCI-c) patients are similar to those used for
diagnosis of AD. These automated tests use imaging and other bio-
marker data, and can now diagnose AD with an accuracy of about
90%, as accurately as expert clinicians can using more traditional
methods. (Beach et al., 2012). While a number of different imaging
modalities have been proposed for this application, the majority
have used structural MRI as atrophy in speciﬁc brain regions is one
of the most established hallmarks of AD. The features used in classiﬁ-
cation derived from structural MRI can take a number of forms, in-
cluding voxel level maps of grey matter density (Fan et al., 2008;
Klöppel et al., 2008; Nho et al., 2010), volume or shape (Barnes et
al., 2004; Ferrarini et al., 2009; Gerardin et al, 2009; Zhang et al.,
2011), or cortical thickness measurements (Desikan et al., 2009;
Eskildsen et al., 2013; Lerch et al., 2008; Querbes et al., 2009). These
features can be calculated over the whole brain or speciﬁc structures
known to be affected by AD, such as the hippocampus. A comprehen-
sive review and comparison of these methods, focused mainly on the
type of MRI-derived features used rather than which machine learn-
ing algorithm was implemented, is given in Cuingnet et al. (2010).
Looking beyond structural MRI, ﬂuorodeoxyglucose positron
emission tomography (FDG-PET) is capable of measuring the level
of glucose metabolism in the brain. Studies have shown that glucose
metabolism is reduced in some regions in patients before they devel-
op AD (Drzezga et al., 2003; Mosconi et al., 2010) and this may be
used to classify AD patients from controls or predict conversion
from MCI to AD (Gray et al., 2012). Biomarkers extracted from cere-
brospinal ﬂuid (CSF) have shown utility in the diagnosis of AD or
MCI. In particular, CSF levels of total tau protein (t-tau) and phos-
phorylated tau (p-tau) proteins, known to be implicated in the forma-
tion of neuroﬁbrillary tangles that cause atrophy in AD, are elevated,
in AD patients, while levels of the amyloid-β42 (aβ42) peptide in CSF
fell (Fjell et al., 2010a; Holtzman, 2011). Measurements of amyloid
load in the brain using amyloid PET have shown similar results
(Rowe et al., 2010). Also, variants of the apolipoprotein E (APOE)
gene affect the risk of developing AD (Corder et al., 1993, 1994).
These different types of biomarker data have been shown to be
complementary, meaning that they provide superior classiﬁcation
when used in combination than when either is used individually,
even if they are correlated (Fjell et al., 2010b; Landau et al., 2010).
Thus a number of studies have sought to make use of multiple bio-
marker types in classiﬁcation. Structural MRI is used in combination
with genetic data in Vemuri et al. (2008) and with CSF biomarkers
in Vemuri et al. (2009) and Davatzikos et al. (2011). Structural MRIdata, FDG-PET and CSF data are used in Hinrichs et al. (2011),
Walhovd et al. (2010) and Zhang et al. (2011). A noteworthy disad-
vantage of multimodal methods is that the problem of missing data
is multiplied, as a subject must be discarded entirely or the missing
data must be synthesised if it is not present in any one of the modal-
ities used. An approach to tackle this issue is presented in (Yuan et al.,
2012).
The most popular classiﬁcation method is the support vector ma-
chine (SVM), due to its accuracy and ability to cope with very high di-
mensional data. Another advantage of the SVM is its ability to use the
kernel, a matrix of size n by n that summarises the distances or co-
variances between n training subjects. This can be applied to learn
from multimodal data. Rather than simply concatenating the features
from different modalities into a single vector, an individual kernel can
be formed from each modality and then a combined kernel generated
as a weighted sum of the individual ones. Both Zhang et al. (2011)
and Hinrichs et al. (2011) use this approach, but ﬁnd the individual
kernel weights in a different fashion, the former choosing them by a
grid search for the weights giving the best accuracy in a nested
cross validation loop, and the latter by optimising them alongside
the standard SVM parameters and with the standard SVM objective
function, a method more broadly known as multiple kernel learning
(Bach et al., 2004).
In this paper we present a different method using a combination
of structural MRI, FDG-PET, CSF and APOE data to classify MCI-s and
MCI-c patients. Primarily, we use Gaussian process (GP) classiﬁcation,
which is a probabilistic classiﬁcation algorithm. Bishop (2007) lists
four general advantages of a probabilistic framework, however for
this particular study we would add twomore which we feel to be par-
ticularly relevant: ﬁrstly, the option to tune free parameters automat-
ically from the training data, avoiding the need for computationally
expensive cross-validation loops, and secondly, that the probabilistic
decisions produced by GP classiﬁcation allow a great deal of ﬂexibility
in their interpretation. Although for convenience, disease is frequent-
ly characterised as a binary distinction, such as healthy or AD patient,
each subject in fact occupies a point on a continuous spectrum of
disease severity, as is reﬂected by the concept of MCI. Probabilistic
classiﬁcation allows us to identify the position of subjects on this
spectrum, enabling disease staging, stratiﬁcation, or event based
modelling (Fonteijn et al., 2012). Probabilistic decisions can also be
made into a binary classiﬁcation simply by thresholding, and our pre-
vious work shows that this method offers accuracy as good as an SVM
on voxel level data for the diagnosis of AD (Young et al., 2012); hence
no diagnostic information is lost by choosing a probabilistic classiﬁca-
tion algorithm. While an SVM's output can be interpreted probabilis-
tically by transforming the decision value with a sigmoid function,
this method is a rather ad hoc modiﬁcation to a binary classiﬁer,
and does not offer the principled formulation and automatic parame-
ter tuning of GP classiﬁcation.
Our previous work is, to our knowledge, the only previous applica-
tion of GP classiﬁcation to AD. GPs have been used previously in a re-
gression context with fMRI data by Marquand et al. (2009), and for
classiﬁcation of structural MRI data in Huntington's disease by Chu
et al. (2010). They have not been previously applied for multimodal
medical image classiﬁcation. Here we use four types of data, and we
compare two methods of setting the kernel weight, one very similar
to that given by Zhang et al. (2011) and the other a probabilistic
method that is more natural within the GP paradigm. We also com-
pare our results to those obtained by an SVM on the same data,
again using the method of Zhang et al. (2011) for setting kernel
weights in the multikernel paradigm.
The training population comprises healthy controls and AD pa-
tients, allowing us to interpret the results in the MCI population as a
risk score for conversion to AD. We introduce a new method for the
validation of probabilistic predictions, which shows that the predict-
ed probability of conversion is a good estimate of the actual chances
Table 1
Demographics of the PET group including 279 subjects. Disease status = diagnosis of
AD or MCI at baseline, with MCI-s or MCI-c decided over 3 year follow-up, n = total
number of subjects in group, n female = total number of female subjects in group,
Mean age = mean age of group in years, Mean MMSE = mean MMSE score of group
in years, SD = standard deviation of measurement.
Disease status n (n female) Mean age (SD) Mean MMSE (SD)
Healthy 73 (27) 75.9 (4.6) 28.9 (1.2)
MCI-s 96 (34) 75.6 (7.0) 27.2 (1.7)
MCI-c 47 (17) 74.5 (7.4) 26.9 (1.8)
AD 63(24) 75.2(6.6) 23.6 (2.0)
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also obtained a binary classiﬁcation into MCI-s and MCI-c by adap-
tively thresholding the probabilities, resulting in a highly accurate
prediction of conversion.
2. Materials and methods
All data were obtained from the Alzheimer's Disease Neuroimaging
Initiative (ADNI) database.1 ADNI was launched in 2003 by the National
Institute on Ageing (NIA), the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Food and Drug Administration (FDA),
private pharmaceutical companies and non-proﬁt organisations, as a
$60 million, 5-year public/private partnership. The primary goal of
ADNI has been to test whether serial MRI, PET, other biological markers,
and clinical and neuropsychological assessment can be combined to
measure the progression of mild MCI and early AD. Determination of
sensitive and speciﬁc markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments and moni-
tor their effectiveness, as well as lessen the time and cost of clinical tri-
als. The Principal Investigator of this initiative is Michael W. Weiner,
MD, VA Medical Center and University of California at San Francisco.
ADNI is the result of efforts of many coinvestigators from a broad
range of academic institutions and private corporations, and subjects
have been recruited from over 50 sites across the U.S. and Canada. The
initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to partici-
pate in the research, approximately 200 cognitively normal older indi-
viduals to be followed for 3 years, 400 people with MCI to be followed
for 3 years and 200 people with early AD to be followed for 2 years.
For up-to-date information, see www.adni-info.org.
2.1. MRI data
Images were all T1 weighted structural MRI scans from 1.5 T scan-
ners acquired using a 3D MPRAGE sequence, taken at the baseline
time point for each subject. Back-to-back scans were taken for each
subject, and the best scan of the pair for each subject determined by vi-
sual inspection. The imageswere then post-processed to correct for gra-
dient warping, B1 non-uniformity and intensity non-uniformity and
underwent phantom based scaling correction. Postprocessed images
were downloaded as DICOM ﬁles, andwere then converted toNIFTI for-
mat for further processing.
2.2. PET data
Images were again all taken from the baseline scan for each in-
cluded subject. Images were acquired by scanning 30–60 min post in-
jection using scanner-speciﬁc protocols. Six ﬁve minute frames are
acquired for each subject, and then co-registered and averaged. The
average images are then rigidly registered to a standard space, and
the individual native space frames registered to the standard space
average and averaged and intensity normalised in the standard
space. Finally, the average images in the standard space are smoothed
with a scanner-speciﬁc kernel (Joshi et al., 2009) to a uniform isotro-
pic resolution of 8 mm FWHM, which is approximately the resolution
of the lowest resolution scanners used in ADNI. The postprocessed
scans were downloaded as DICOM images.
2.3. APOE data
Variants of the apolipoprotein E (APOE) genotype are known to af-
fect the risk of developing sporadic AD in their carriers. Each individ-
ual has two copies of this gene, one inherited from each parent. The
most common allele is APOE ε3, but carriers of the APOE ε4 variant
are at heightened risk of AD, whereas the APOE ε2 variant confers
some protection on carriers (Corder et al., 1993, 1994). The APOE ge-
notype of each subject was recorded as a pair of numbers indicatingwhich two alleles were present. APOE genotype is determined from
a 10 ml blood sample taken at screening time, and sent overnight to
the University of Pennsylvania AD Biomarker Fluid Bank Laboratory
for analysis. APOE genotype was available for all subjects for which
we had imaging data.2.4. CSF data
CSF samples of 20 ml volume were obtained from subjects by a
lumbar puncture with a 24 or 25 gauge atraumatic needle around
the time of their baseline scan. All samples were sent on dry ice on
the same day as they were drawn to the University of Pennsylvania
AD Biomarker Fluid Bank Laboratory, where levels of the proteins
(aβ42, total tau, and phosphorylated tau) were measured and recorded.
By design, only a subset of ADNI subjects had measurement of CSF
levels. All three measured protein levels (t-tau, p-tau, and aβ42) were
used in constructing a CSF kernel.2.5. Subjects
All ADNI subjects were between 55 and 90 years old, speak
English or Spanish, and had a study partner able to provide an inde-
pendent assessment of functioning. All subjects were willing to un-
dergo neuroimaging and agreed to longitudinal follow up, and a
subset was willing to undergo lumbar punctures. Subjects with spe-
ciﬁc psychoactive medication were excluded. Inclusion criteria for
healthy controls (HC) are MMSE scores between 24 and 30, a CDR
of 0, non-depressed and non-demented. Ages of the HC subjects
were roughly matched to those of the AD and MCI subjects. For MCI
subjects, the criteria are an MMSE score between 24 and 30, a mem-
ory complaint, objective memory loss measured by education adjust-
ed scores on Wechsler Memory Scale Logical Memory II, a CDR of 0.5,
absence of signiﬁcant levels of impairment in other cognitive do-
mains, essentially preserved activities of daily living, and an absence
of dementia.
For AD subjects, the criteria are an MMSE score between 20 and
26, CDR of 0.5 or 1.0, and meeting NINCDS/ADRDA criteria for proba-
ble AD. Subjects are designated as HC, AD or MCI at the time of the
baseline scan, and for the purposes of this study MCI conversion sta-
tus is decided by whether subjects who were MCI at baseline were
subsequently diagnosed as AD at any stage during the subsequent
36 month follow-up period.
A total of 682 subjects with baseline 1.5 T MRI scans were avail-
able. Of these, the image parcellation procedure was run on 679, the
manually generated brain masks required for the parcellation being
unavailable for three. Of these 679 subjects, FDG-PET scans were
also available for 286. Seven of these were diagnosed as MCI at base-
line but as healthy at follow-up time points and were excluded as re-
verters, leaving a total of 279 subjects available for the study. The
demographics of this group (referred to as the PET group) are given
in Table 1.
Table 4
Selected regions for classiﬁcation.
Label numbers Regions
1, 2 Hippocampus (R and L)
3, 4 Amygdala (R and L)
5, 6 Anterior temporal lobe, medial part (R and L)
7, 8 Anterior temporal lobe, lateral part (R and L)
9, 10 Parahippocampal and ambient gyri (R and L)
11, 12 Superior temporal gyrus, posterior part (R and L)
13, 14 Middle and inferior temporal gyrus (R and L)
15, 16 Fusiform gyrus (R and L)
24, 25 Cingulate gyrus, anterior part (R and L)
26, 27 Cingulate gyrus, posterior part (R and L)
Table 2
Demographics of the PET-CSF group including 143 subjects. Disease status = diagnosis
of AD or MCI at baseline, with MCI-s or MCI-c decided over 3 year follow-up, n = total
number of subjects in group, n female = total number of female subjects in group,
Mean age = mean age of group in years, Mean MMSE = mean MMSE score of group
in years, SD = standard deviation of measurement.
Disease status n (n female) Mean age (SD) Mean MMSE (SD)
Healthy 36 (12) 74.2 (4.2) 28.8 (1.3)
MCI-s 42 (16) 75.4 (7.0) 27.3 (1.6)
MCI-c 30 (11) 75.5 (7.6) 26.5 (1.8)
AD 35 (12) 75.2 (6.7) 23.9 (2.0)
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siﬁcation. As there was relatively little overlap between the groups
of patients given CSF biomarker testing as well as FDG-PET scans,
the subset of the PET group for which full CSF data was also available
(referred to as the PET-CSF group) was much smaller at a total
143 subjects. The demographics of the PET-CSF group are given in
Table 2.
In the PET group, 47 out of 143 (33%) of MCI subjects are con-
verters. As conversion is deﬁned over a 3 year follow-up period, this
is equivalent to an annualised conversion rate of 12.5% per year, in
line with other studies. Subjects diagnosed as MCI at baseline in
ADNI are reassessed after approximately 6, 12, 18, 24 and 36 months
which allow us to roughly ﬁnd the time after which they converted.
The conversion times for the 47 MCI-c subjects in the PET group are
listed in Table 3.
2.6. MRI image processing
To produce grey matter (GM) probability maps in a common
space for classiﬁcation, we follow roughly the same procedure as
Klöppel et al. (2008). However we use different image processing
software, and also add a step of masking the images to include only
regions known to be affected by AD.
2.6.1. Image segmentation
The native space, preprocessed scans were probabilistically seg-
mented using the open source NiftySeg tool (Cardoso et al., 2011).
Based on the expectation maximisation algorithm, this method pro-
duces probabilistic maps for ﬁve tissue types: white matter, cortical
GM, external cerebrospinal ﬂuid, deep GM and internal cerebrospinal
ﬂuid.
2.6.2. Image parcellation
The native space, preprocessed scans were also anatomically
parcellated into 83 regions. This was with a multi-atlas segmentation
propagation algorithm (Cardoso et al., 2012). A library of 30 atlases
manually labelled with 83 anatomical regions (Gousias et al., 2008)
was used as a basis for the segmentations. In order to segment a
new image, all the atlases and respective manual labels were ﬁrst
nonrigidly registered to this image. After registration, the manualTable 3
Conversion times of MCI-c subjects in the PET group.
Conversion time = time after baseline scan when
the subject was ﬁrst diagnosed as AD, n = total
number of subjects in group.
Conversion time t (months) n
t b 6 5
6 b t b 12 15
12 b t b 18 9
18 b t b 24 14
24 b t b 36 4labels of the locally most similar atlases were fused using a label fu-
sion strategy based on an extension of the STAPLE algorithm
(Warﬁeld et al., 2004) to produce a ﬁnal parcellation. The regions
used in the classiﬁcation process were chosen according to Braak
and Braak (1995) and are listed in Table 4. These regions were then
intersected with the GM tissue segmentations obtained above.
2.6.3. Image registration
All images were transformed into the same anatomical space in
order to provide consistent anatomy at each voxel for the classiﬁer.
The images were masked to remove non-brain material, and then
used to perform groupwise registration. All images were repeatedly
registered to the same target image in an iterative procedure. At the
end of each iteration, all registered images were averaged together
to create an updated target image, with a randomly chosen image
serving as the target in the ﬁrst iteration. Initially, all images were rig-
idly registered to avoid bias towards the chosen target. This was
followed by a single round of afﬁne registration, and then by 10
rounds of nonrigid registrations. All registrations were performed
using NiftyReg (Modat et al., 2010), a registration toolkit that per-
forms fast diffeomorphic nonrigid registrations. When the registra-
tions had all been completed, the resulting deformations from each
image's native space to the ﬁnal average image were applied to the
anatomically masked native space segmentations to bring them into
the groupwise space. The registered, anatomically masked segmenta-
tions were modulated by the Jacobian determinants of this ﬁnal de-
formation. This ensures that the total volume of tissue remains
constant (Ashburner and Friston, 2000). As a ﬁnal step, the registered,
anatomically masked and Jacobian modulated cortical GM and deep
GM segmentations were summed to produce an overall GM density
map for the AD relevant regions in a common space for all subjects.
2.7. PET image processing
The PET images had already been through substantial postprocessing,
as discussed above. After downloading, they were registered to the na-
tive space MRI image of the same subject, again using the NiftyReg soft-
ware. Then masks generated from the structural MRI parcellations were
overlaid on each subject to calculate the total activity within each region
from the PET image. Themean activitywithin each regionwas then used
as a feature for classiﬁcation.
2.8. Gaussian processes
The resulting high dimensional image and biomarker data were
then used to construct a GP classiﬁer based on HC and AD subjects.
A full description of GP classiﬁcation is beyond the scope of this
study. We refer readers to Rasmussen and Williams (2006) for a de-
tailed theoretical treatment, and to our earlier work (Young et al.,
2012) for an example of their application to AD image classiﬁcation.
Instead, we give a brief description of GP classiﬁcation and give fur-
ther details on the aspects that pertain to multimodal classiﬁcation.
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the GPML toolbox2 for MATLAB3 which was also used to analyze
results.
2.8.1. Gaussian process classiﬁcation
Gaussian process classiﬁcation can be seen as kernelised Bayesian
extension of logistic regression. A Gaussian process, essentially a mul-
tivariate Gaussian, forms the prior on the value of a latent function,
which is then mapped to the (0,1) interval through a sigmoid,
which represents the probability of a subject belonging to a particular
class. The exact prior is a function of the training data and labels, and
a set of hyperparameters that control the shape of the prior. During
the training phase, the hyperparameters are learned from the training
data and labels by type-II maximum likelihood. The likelihood of
the training data and labels with respect to the hyperparameters is
maximised using a conjugate gradient descent optimisation method.
Once the hyperparameters have been set, predictions on unseen data
are made by integrating across this prior. In the regression case, this is
analytically tractable, but for classiﬁcation it is not, due to the sigmoidal
response function, so an approximation must be made instead. A
number of different approximation schemes can be used, but all our ex-
periments use the expectation propagation algorithm (Minka, 2001).
This has been shown to offer a good compromise of accuracy and com-
putation time for GP classiﬁcation (Nickisch and Rasmussen, 2008).
2.8.2. Gaussian processes as multimodal kernel methods
Note that theGP classiﬁer is based on a kernel K representing the co-
variance among training subjects. This is a symmetric positive deﬁnite
matrix where entry (i,j) is a covariance or some function of distance be-
tween training subjects i and j. As such, thismeans that GP classiﬁcation
belongs to the family of kernel methods as do SVMs, and all the rules for
constructing valid kernels apply: in particular, a positive sum of valid
kernels is a valid kernel, and a valid kernel multiplied by a positive sca-
lar is also a valid kernel. The covariance between the ith and jth subject,
Kij, is a kernel function k of the feature vectors for the ith and jth subject
xi and xj and a hyperparameter or hyperparameters θ. We use a linear
kernel function, which is the scalar product of xi and xj plus a single
hyperparameter representing a bias term: Ki,j = xi ⋅ xj + θ. The
hyperparameter is learnt from the training data by type-II maximum
likelihood. For multimodal classiﬁcation, the rules for producing new
kernel mean that we can deﬁne our kernel function as the weighted
sum of a number of subkernels, each of which has been calculated
from a the feature vectors representing a particular type of data or mo-
dality for each subject. Each subkernel has a scaling hyperparameter
representing the modality's weight in the overall kernel, which also in-
cludes a single bias term. So in the case of multimodal classiﬁcation
using each subject's MRI, PET and APOE data the overall kernel is
Ki;j ¼ αMRI xMRI;i⋅xMRI;j
 
þ αPET xPET;i⋅xPET;j
 
þ αAPOE xAPOE;i⋅xAPOE;j
 
þ β
where α are hyperparameters representing the weight given to each
modality subkernel, and β is a hyperparameter representing the bias
in the combined kernel. Thus θ is now a set of four hyperparameters
which are again learnt from the training data by maximum likelihood.
In this way we can automatically set the kernel weights without need-
ing to resort to a grid searchwith cross validation. This is possible as the
GPML software allows complex covariance functions to be speciﬁed. It
allows us to applymasks to include only certain columns of the training
data to be used in a covariance function, so we can learn separate co-
variance kernels for the MRI, PET and APOE data. The APOE kernel is
based on representing each subject as a vector of length two, encoding2 http://www.gaussianprocess.org/gpmlcode/matlab/doc.
3 MathWorks Inc., Natick, MA, 2011.each allele as an element of the vector, so for a example a subject with
one copy of the ε3 allele and one of the ε4 would be encoded as (3 4).
More sophisticated kernels have been developed for genetic data and
we plan to exploit these in future.
For the PET group, we also do a grid search for the kernel weights to
compare the results of this method of setting the kernel weights to the
maximum likelihood method and to Zhang et al. (2011). Each MCI test
subject in turn is left out, and a GP classiﬁer is trained on all AD and
control training subjects for each legitimate combination of α. The
best values of α are chosen empirically as the ones offering the most
accurate classiﬁcation on the n-1 remaining MCI test subjects. As accu-
racy is a coarse measure, any ties are broken with the information the-
ory based metric of classiﬁcation quality suggested by Rasmussen and
Williams (2006). Finally the classiﬁer offering the best accuracy was
tested on the left out MCI subject, and the process repeated until all
MCI test subjects had been classiﬁed. Due to the leave-one-out loop
and the need to do one tuning classiﬁcation for every combination of
parameters within each iteration of the loop, this method is very time
consuming if more than a handful of parameters have to be tuned.
Hence to make the whole classiﬁcation procedure tractable, values of
α are constrained to be positive and sum to one, with no bias term,
as in Zhang et al. (2011). The resulting two-dimensional parameter
space is searched with increments of 0.1 for both parameters.
Fig. 1 represents the multikernel approach.
2.9. SVM classiﬁcation
To put the results obtained by GP classiﬁcation in context and
compare them to a more widely used method we also performed
SVM classiﬁcation on the same datasets. We made use of the open
source libsvm library,4 with the C parameter left at its default setting
and linear kernels, but used precomputed kernels both for the sake of
speed and to facilitate multikernel classiﬁcation. Training and testing
kernels were constructed for all three modalities in the PET group
(MRI, PET and APOE) and all four in the PET-CSF group (MRI, PET,
APOE and CSF). Kernel weights are again set using the method of
Zhang et al. (2011) as described in the previous section. The weight
setting is done within a leave one out scheme, where the testing
(MCI-s and MCI-c) subjects are repeatedly split into one subject used
for testing and the remaining ones used for tuning the kernel weights
until each MCI subject has been left out; in this way it is possible to
tune on the testing population without introducing optimistic bias
(Kriegeskorte et al., 2009). We also tried to set the kernel weights
using the training (NC and AD) subjects for tuning, by performing a
leave-one-out cross validation on the training subjects at each legitimate
combination of kernel weights. To break ties between parameter set-
tings showing equal accuracy, we use the mean distance from the mar-
gin of correctly classiﬁed test subjects minus themean distance from the
margin of incorrectly classiﬁed test subjects as a metric of SVM quality.
We also experimented with normalising training and testing data
using a z-score to help combine different modalities on the same scale.
2.10. Classiﬁcation strategy
Rather than both training and testing the classiﬁer on MCI-s and
MCI-c subjects in a cross-validation loop, we train on AD and healthy
subjects, and then obtain results by applying the resulting classiﬁer to
the MCI population. This approach to classiﬁcation of MCI subjects is
widely used and was adopted here as it obtained substantially better
results than those obtained by the training on MCI regime in all our
preliminary work. The hypothesis justifying this is that the subpopu-
lation of MCI subjects that are stable are more healthy-like (although
some will go on to convert beyond the follow up period used for4 http://www.csie.ntu.edu.tw/~cjlin/libsvm/.
α
α
α
Fig. 1. Pipeline by which kernels are constructed from features extracted from each type of data, before being summed to produce a combined kernel.
740 J. Young et al. / NeuroImage: Clinical 2 (2013) 735–745deﬁning conversion, which is probably a factor in the limited accuracy
of predictions of MCI conversion), while those who go on to develop
dementia are more AD-like, as is consistent with our contention that
discrete disease states are an approximation to a continuous disease
spectrum.
This means a classiﬁer that successfully separates AD and control
subjects will also be able to distinguish between MCI-c and MCI-s to
some degree. This notion, illustrated in Fig. 2, has been used with
some success for this problem previously (Ferrarini et al., 2009;
Singh et al., 2012). As previously mentioned, however, when using aFig. 2. Relation between AD and MCI classiﬁcation.combined kernel with grid search we can use the MCI subjects not
being classiﬁed to tune the kernel mixing parameters.
2.11. Validation
The results of GP classiﬁcation are numbers between 0 and 1
representing the estimated probability that a test subject belongs to
a particular class, in our case the class of MCI-c. A simple way to
binarise these probabilities is to threshold them at 0.5. We do this,
and report the resulting accuracy, sensitivity and speciﬁcity. However
this approach has two disadvantages. Firstly, as the model is trained
on one population (AD and control) and tested on another (MCI-s
and MCI-c), this would be the correct threshold value if the test pop-
ulation were in some sense exactly half way between the two classes
of the training population, but there is no reason to believe this is nec-
essarily the case. Secondly, setting the cut point at 0.5 leads to varying
balances between sensitivity and speciﬁcity among the different
methods, making them hard to compare. Because of this, we also
use the test probabilities to determine the cut point that results in
the closest possible value of sensitivity and speciﬁcity. We then deter-
mine the overall correct classiﬁcation rate at this cut point and report
only that, as by deﬁnition it will be very close to both the sensitivity
and speciﬁcity. This is done in a leave-one-out framework to avoid
optimistic bias in the balanced accuracy. We also use the probabilities
to calculate the area under the receiver operating characteristics
(ROC) curve, known as the AUC, for easy comparison with results
from other studies. For both PET and PET-CSF groups we also report
the balanced accuracy for classiﬁcation using each modality alone, ex-
cept for the APOE. This is left out because APOE data consists of pairs
of alleles labelled 2, 3 or 4. As order does not matter this means each
subject can be at one of only 6 points in two-dimensional APOE data
Table 6
Accuracy of methods on the PET group with SVM classiﬁcation. Acc = accuracy,
sens = speciﬁcity, spec = speciﬁcity, balanced acc = balanced accuracy, and AUC =
area under the ROC curve.
Modality acc sens spec Balanced acc AUC
MRI 58.7% 53.2% 61.5% 58.7% 0.629
PET 69.9% 55.3% 77.1% 67.1% 0.762
MRI + PET + APOE (GS) 65.7% 68.1% 64.6% 67.8% 0.731
741J. Young et al. / NeuroImage: Clinical 2 (2013) 735–745space (in practice 5 points as one combination does not occur in our
data), so an APOE only classiﬁer would produce probabilities that
could only be one of ﬁve discrete values, making further analysis
meaningless. We assess the signiﬁcance of the difference in balanced
accuracy between multimodal classiﬁcation and unimodal classiﬁca-
tion for both the PET group and PET-CSF group with McNemar's test
(McNemar, 1947) if there appears to be a substantial difference. The
balanced accuracies are derived from the probabilities before they
are corrected for bias with the procedure described in Section 3.2.
We found that balanced binary accuracies derived from the corrected
probabilities tended to be slightly lower.
However, to only do this would be to neglect the probabilistic in-
formation contained in the output of the GP. We can also treat the
probabilities as risk scores for conversion to AD, and determine how
well they function as estimates of the actual chances of conversion.
As each subject either does or does not convert to AD, this cannot
be assessed at the individual level. We instead bin all MCI subjects
into eight equal intervals covering the range (0,1) by their risk
score. For each of the eight intervals, the centre value of the interval
is labelled the predicted risk. We then calculate the empirical risk for
each interval as the proportion of patients in the interval that do in
fact convert. Finally, the root mean square error between predicted
and empirical risk is calculated as a measure of howwell the risk scores
from GP classiﬁcation predict the actual risk of conversion. The number
of intervals was chosen to provide the best balance between the
demands for good statistics both within and between the bins.
The decision values obtained from SVM classiﬁcation represent a
signed distance from the optimal hyperplane determined from the
training data, the sign indicating on which side of the hyperplane a
test subject falls and thus to which class it is predicted to belong.
We report the accuracy, sensitivity and speciﬁcity from the sign of
the decision values (equivalent to thresholding the decision values
at 0). We also perform a procedure to ﬁnd the threshold producing
the accuracy that best balances sensitivity and speciﬁcity in the
same manner as we did for GP posterior probabilities, and ﬁnally cal-
culate an AUC from the decision values.
3. Results
3.1. Accuracy of binary classiﬁcation
The balanced accuracy, AUC, and p-value for comparison of multi-
modal methods with unimodal ones for the PET group are shown in
Table 5 for the GP results, and in Table 6 for the SVM results.
The result in the last row of Table 6 was obtained by using the MCI
subjects as a tuning set, and normalising training data with a z-score,
and then normalising testing data using the mean and standard devi-
ations from the un-normalised training data. All other combinations
of choices of tuning set and normalisation produced inferior results.
The same accuracy measures for the PET-CSF group are shown in
Table 7 for GP classiﬁcation and Table 8 for SVM. For the GP, we do
not perform the grid search method due to the increased computa-
tional demands of having to do a three dimensional grid search for
four modalities, rather than a two dimensional grid search for threeTable 5
Accuracy of methods on the PET group with GP classiﬁcation. Acc = accuracy, sens =
speciﬁcity, spec = speciﬁcity, balanced acc = balanced accuracy, AUC = area under
the ROC curve, and p = signiﬁcance of improvement in classiﬁcation vs. indicated sin-
gle modality.
Modality acc sens spec Balanced
acc
AUC p vs.
MRI
p vs.
PET
MRI 64.3% 53.2% 69.8% 61.5% 0.643 – –
PET 65.0% 66.0% 64.6% 65.7% 0.767 – –
MRI + PET + APOE (ML) 69.9% 78.7% 65.6% 74.1% 0.795 0.0162 0.0247
MRI + PET + APOE (GS) 67.1% 76.6% 62.5% 70.6% 0.751 0.0865 0.2301modalities as in the previous experiment. We do, however, report
the results for multimodal classiﬁcation both with and without the
CSF data so it is possible to see its effect on classiﬁcation with a con-
sistent set of test subjects.
Again, the last two rows of Table 8 present results obtained using
MCI subjects for tuning the kernel weights, and with the data
normalised with a z-score as these provided the best accuracy.
The results show a clear advantage in accuracy for multimodal im-
aging. In the larger PET group, both multimodal algorithms are better
than any single modality alone. This advantage is statistically signiﬁ-
cant at the 5% level for the type-II maximum likelihood method with
GP classiﬁcation, which outperforms the grid search method and out-
performs the best single modality by over 8%. The AUC measure of ac-
curacy shows how results must be interpreted with caution, as the
multimodal grid search method has a higher balanced accuracy than
using PET alone, but offers a slightly lower AUC. In the smaller
group for which both PET and CSF data were available in all subjects,
the same pattern applied in that multimodal methods outperformed
all single modality methods.
To enable a side-by-side comparison, Table 9 shows the balanced
accuracy for GP and SVM classiﬁcation together with a p-value for
the difference in accuracy. The p-value is generated by classifying all
test subjects with the leave-one-out procedure used to generate the
balanced accuracy ﬁgures, and comparing the resulting classiﬁca-
tions, again using McNemar's test.
3.2. Accuracy of probabilistic classiﬁcation
The predicted risk ﬁgures produced in the manner described
in Section 2.11 exhibit some bias, in that the classiﬁers tend to
overestimate the chances of conversion in general. This appears to
be because of the transfer learning approach we use, where the clas-
siﬁer is trained on the AD and healthy population, and then applied to
the MCI subjects. As the MCI subjects, in terms of the biomarker data
we use, are not midway between the AD and control population but
slightly closer to the AD subjects, this results in the classiﬁer being
somewhat biased in favour of predicting conversion. In order to re-
move this, we perform a correction procedure on the GP probabilities
similar in approach to the one used to produce a balanced accuracy.
We perform a logistic regression, using a leave-one-out approach
again to avoid unduly optimistic results, on the GP probabilities and
the labels indicating converter or stable status for the MCI subjects,
with the label 0 indicating stable and 1 indicating converter. In this
way we can learn the relationship between GP predicted risk and ac-
tual risk for the MCI subjects to correct for the bias. The resulting plots
of empirical risk versus adjusted predicted risk for the PET and
PET-CSF groups are shown in Figs. 3 and 4. Plotted points are labelled
with the number of subjects in the corresponding bin. As not all the
bins contain subjects, points for these bins are not included.
In these plots, a classiﬁer producing accurate probabilities should
have points plotted close to the diagonal. By inspection, the multi-
modal methods appear to perform well by this measure, and it is im-
portant to note that most points lying far away from the diagonal
represent bins containing few subjects, making the empirical risk cal-
culated for them less reliable. More broadly, the probabilities pro-
duced by GP classiﬁcation procedure appear to be accurate in the
Table 8
Accuracy of methods on the PET-CSF group with SVM classiﬁcation. Acc = accuracy,
sens = speciﬁcity, spec = speciﬁcity, balanced acc = balanced accuracy, and
AUC = area under the ROC curve.
Modality acc sens spec Balanced acc AUC
MRI 65.3% 76.7% 57.1% 63.9% 0.685
PET 69.4% 63.3% 73.8% 65.3% 0.782
CSF 56.9% 73.3% 45.2% 55.6% 0.575
MRI + PET + APOE (GS) 68.1% 76.7% 61.9% 68.1% 0.745
MRI + PET + APOE + CSF (GS) 66.7% 76.7% 59.5% 69.4% 0.727
Table 7
Accuracy of methods on the PET-CSF group with GP classiﬁcation. Acc = accuracy, sens = speciﬁcity, spec = speciﬁcity, balanced acc = balanced accuracy, AUC = area under the
ROC curve, and p = signiﬁcance of improvement in classiﬁcation vs. indicated single modality.
Modality acc sens spec Balanced acc AUC p vs. MRI p vs. PET p vs. CSF
MRI 63.9% 76.7% 54.8% 61.1% 0.682 – – –
PET 66.7% 80.0% 57.1% 69.4% 0.789 – – –
CSF 55.6% 73.3% 42.9% 56.9% 0.575 – – –
MRI + PET + APOE (ML) 68.1% 83.3% 57.1% 72.2% 0.823 0.1860 0.7728 0.0725
MRI + PET + APOE + CSF (ML) 68.1% 90.0% 52.4% 72.2% 0.763 0.2012 0.8231 0.0153
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imply an increased chance of conversion actually taking place. The
adjustment appears to be effective, with little bias exhibited in the
predicted risks. Note that the only points which are plotted very far
from the diagonal, and thus show a large difference between empiri-
cal and predicted risk, are of risk bins containing only 1 or 2 subjects
and are simply the results of outliers.0.5
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PET only4. Discussion
As previously stated, a clear advantage can be seen both for multi-
modal classiﬁcation, and for the use of GP classiﬁcation over the more
widely used SVM. This applied to results for both the PET and PET-CSF
groups. Moreover, there appears to be quite a strong interaction be-
tween the utility of multimodal classiﬁcation and the type of classiﬁer
used. Looking at the balanced accuracy of classiﬁcation on single mo-
dalities of data, there is little to choose between GP and SVM classiﬁ-
cation, with differences of one or two per cent in accuracy in either
direction. Thus, it seems reasonable to conclude by this measure
that there is little difference in discriminative ability on identical
sets of data. However, the GP framework appears to be able to take
much greater advantage of the availability of multimodal data. GPs
offer much larger gains for multimodal versus unimodal classiﬁcation,
with gains of 8% in the PET group against the best single data (PET) as
against only a 0.7% gain for the SVM approach. Similarly, the
head-to-head comparisons between the GP and SVM methods using
the same subjects and modalities, in Table 9, show the greatest differ-
ences in classiﬁcation accuracy and greatest statistical signiﬁcance are
for the multimodal methods. While the difference is not quite signif-
icant at the 0.05 level, due to the relatively small number of subjectsTable 9
Statistical comparison of GP and SVM classiﬁcation results.
Group Modality Balanced
accuracy
(GP)
Balanced
accuracy
(SVM)
p-Value for
accuracy of
GP vs. SVM
PET MRI 61.5% 58.7% 0.3865
PET PET 65.7% 67.1% 0.7893
PET MRI + PET + APOE 74.1% 67.8% 0.1508
PET-CSF MRI 61.1% 63.9% 0.6831
PET-CSF PET 69.4% 65.3% 0.4497
PET-CSF CSF 56.9% 55.6% 1
PET-CSF MRI + PET + APOE 72.2% 68.1% 0.4497
PET-CSF MRI + PET + APOE + CSF 72.2% 69.4% 0.8026in the study, the advantage for GP against SVM classiﬁcation is clear
and consistent across all three multimodal classiﬁcation experiments
and we plan to verify it with a larger dataset.
The improvement is most likely because the GP framework is bet-
ter at ﬁnding a set of kernel weights for optimum classiﬁcation. With
an SVM we are restricted to ﬁnding these through a grid search,
which has an inherently limited range and resolution if it is to be trac-
table, and is dependent on rather crude measures of accuracy to select
an optimal parameter set. GPs offer tuning via the likelihood function,
which seems to be both more robust and allows a wider search space
— however this is not available for SVM classiﬁcation, highlighting
one of the advantages of a probabilistic framework mentioned in
the introduction.
Adding CSF to multimodal classiﬁcation did not increase the accu-
racy by any signiﬁcant amount and in fact decreased the AUC, which
is not surprising as CSF is the poorest single modality, offering accura-
cy little better than chance. The poor performance of CSF biomarkers
alone, and their failure to add diagnostic value when used alongside
other biomarkers, is perhaps explained by the fact that about a third
of controls have a high amyloid load, suggesting they may be in fact
at a presymptomatic stage of AD. In this case CSF is still a potentially
valuable biomarker, but our choice of deﬁning AD and control sub-
jects purely by current symptoms and cognitive test results limits
its applicability. This again suggests the need to treat AD as a spec-
trum rather than a set of discrete states, or at least to very carefully
deﬁne such states.
Comparing the results presented here to other attempts to predict
conversion in MCI patients is difﬁcult. This is because, while the prob-
lem has been addressed in a large number of studies, these vary0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
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siﬁcation accuracy is assessed. However the method presented here
certainly offers a high level of classiﬁcation accuracy, especially con-
sidering studies that use ADNI data and offer higher accuracy make
predictions over a time span of less than three years or make use of
longitudinal data, which our algorithm does not need.
For MRI data, the most comparable methods are in Cuingnet et al.
(2010). This study included a wide variety of types of feature, but
those which used voxel level GM maps are quite similar to our
work. Even within this deﬁnition, a wide range of options in image
processing and feature extraction were used but the closest in meth-
odology to ours is what they label as the Voxel-Direct-D-GM method.
When applied to predicting MCI conversion this was found to have a
speciﬁcity of 100% and sensitivity of 0%, i.e. The classiﬁer simply
assigned all subjects to the majority MCI-s class, possibly as a function
of having trained on MCI-s and MCI-c rather than control and AD sub-
jects. This paper did also ﬁnd that the voxel based method in Fan et al.
(2008) achieved a sensitivity of 62% and speciﬁcity of 67%, although
this was found not to be signiﬁcantly greater than chance. Our meth-
od achieves much greater accuracy than any in Cuingnet et al. (2010)
for predicting MCI conversion, and moreover our accuracy is statisti-
cally signiﬁcantly better than chance, which none of the methods
assessed that study managed to achieve.Table 10
Reported results from a variety of studies for predicting MCI conversion on ADNI data. n =
deﬁned, acc = accuracy in predicting conversion, if reported, and AUC = area under ROC c
Article Data used n (MC
Young et al. MRI, FDG-PET, APOE 143 (9
Eskildsen et al. MRI 388 (2
Ye et al. MRI, APOE, cognitive scores 319 (1
Wee et al. MRI 200 (1
Zhang et al. MRI, FDG-PET,CSF 99 (56
Hinrichs et al. Longitudinal/baseline MRI, longitudinal/baseline
FDG-PET, CSF, APOE, cognitive scores
119
Coupé et al. MRI 405 (2
Wolz et al. MRI 405 (2
Nho et al. MRI, APOE, family history 355 (2
Davatzikos et al. MRI, CSF 239 (1Other studies, however, have hadmuchgreater success in predicting
conversion. For example, Coupé et al. (2012) and Eskildsen et al. (2013)
have presented methods capable of predicting conversion with accura-
cies similar to ours. Coupé et al. (2012) uses a novel hippocampal grad-
ing biomarker. Using their most rigorous validation method, accuracy
was slightly lower at 71% but their method needs no FDG-PET data
and less computationally intensive image processing than the one
presented here. Eskildsen et al. (2013) also achieves 74% accuracy by
stratifying MCI-C subjects by conversion time and then combining the
results of classifying each MCI-C subgroup against the MCI-s subjects.
The classiﬁer is rather unbalanced, with substantially higher speciﬁcity
than sensitivity, a common problem with MCI classiﬁcation, but again
only structural image data is needed. Ye et al. (2012) report AUC values
of up to 0.85 usingMRI data, APOE genotypes, and a variety of cognitive
measures with a sparse logistic regression procedure but do not list
classiﬁcation accuracy. Wee et al. (2012) use features based on correla-
tions betweenmean thicknesses of cortical regions of interestwith SVM
classiﬁcation, and obtain 75% accuracy and an AUC of 0.8426.
Among multimodal methods, Zhang et al. (2011) reports a speci-
ﬁcity of 91.5% and a speciﬁcity of 73.4% for prediction of MCI conver-
sion. While they do not report the proportions of MCI-s and MCI-c in
their subjects and hence we cannot calculate the overall accuracy, it
must be greater than our best result of 74%. However, they deﬁne
conversion as a subject converting within 18 months rather than
three years. Predicting over a short future timespan is an easier prob-
lem than over a longer one (Eskildsen et al., 2013) and less clinically
useful. Moreover, deﬁning conversion over a shorter time means a
smaller proportion of MCI subjects will be converters, reducing the
positive predictive value of the classiﬁcation result. Additionally,
their work uses CSF data in addition to MRI and FDG-PET, whereas
our best performing classiﬁer uses genetic data instead of CSF,
which is easier and less invasively obtained. We are able to set our
kernel weights by type-II maximum likelihood, avoiding the need
for a computationally expensive grid search. The other previously
published multikernel method to predict MCI conversion is by
Hinrichs et al. (2011). Although they do deﬁne converters with a
three year time span, direct comparison of results is again difﬁcult,
as they report only an AUC rather than accuracy. The best reported
AUC was 0.791, similar to ours but this used longitudinal data, again
effectively reducing the time span to predict conversion. They also
found the method using only longitudinal image data was more effec-
tive than including non-imaging data in their multikernel learning
approach. Methods based on features structural imaging alone are
also capable of achieving high accuracy.
Table 10 summarises these results in comparison with our own.
Table 10 clearly shows the difﬁculty in making direct comparisons
between results. For example, the time within which MCI conversion
is deﬁned has a strong effect on results. Vounou et al. (2012) used
tensor based morphometry to deﬁne a set of voxels that are highly in-
dicative of MCI conversion, and then applied an SVM to these. Thisnumber of subjects, conversion period = length of time over which MCI conversion is
urve of predictions of conversion, if reported.
I-s, MCI-c) Conversion period acc AUC
6, 47) 0–36 months 74.1% 0.795
27, 161) 0–36 months 73.5% –
77, 142) 0–48 months – 0.8587
11, 89) 0–36 months 75.05% 0.8426
, 43) 0–18 months sens 91.5%, spec 73.4% –
0–36 months – 0.7911
38, 167) 0–36 months 73% -
38, 167) 0–36 months 68% –
05, 150) 0–36 months 71.6% –
70, 69) 0–36 months 61.7% 0.734
744 J. Young et al. / NeuroImage: Clinical 2 (2013) 735–745method was able to predict conversion with an accuracy of 82%. As
this method uses both baseline MRI scans and 24 month follow-up
MRI scans to generate Jacobian maps, it is effectively predicting con-
version in only a 12 month period rather than three years as we do,
and longitudinal data may not be available in all cases.
Parameterisations of the shape of the hippocampus have achieved
a greater accuracy than our approach with conversion deﬁned over
three years (Costafreda et al., 2011; Ferrarini et al., 2009), however
these used a small number of subjects scanned at a single centre,
and also had autopsy conﬁrmed AD subjects available, removing any
uncertainty in the training labels. If conversion is deﬁned over a three
year period, we believe our method presented here has obtained an
accuracy very competitive with the best methods yet published for
prediction of conversion to date on ADNI data.
Moreover, our method offers the advantages of probabilistic clas-
siﬁcation listed in Section 1. The reject option is especially relevant
in the case of computer-aided diagnosis. Having a probabilistic classi-
ﬁcation means that each diagnosis includes an attached degree of
conﬁdence rather than a simple binary decision. Clinical decision
making is frequently hampered by overconﬁdence (Berner and
Graber, 2008), so an estimate of the certainty of a diagnosis could
be of great help, if only as a supplement to decisions made by more
traditional methods.
5. Conclusion
We have shown that multimodal Gaussian process classiﬁers can
be successfully applied to the prediction of conversion to AD in MCI
patients. Prediction of conversion is signiﬁcantly better for multimod-
al classiﬁcation than for any single modality, and also better for GP
compared to SVM classiﬁcation, largely due to the GP's superior abil-
ity to exploit multimodal data. Accuracy is state-of-the-art, and to this
we can add the advantages of probabilistic classiﬁcation. In the future,
we plan to take advantage of new subjects with FDG-PET and CSF data
being added to the ADNI database and apply these methods to a larg-
er group of subjects to show greater statistical signiﬁcance for the ad-
vantage of our methods. We will perform more sophisticated feature
extraction on FDG-PET data and to make use of more complex kernel
covariance functions. We also plan to investigate other promising bio-
markers such as hippocampal shape and cortical thickness, and will
examine methods to overcome the problem of misdiagnosis leading
to noisy training labels in ADNI data.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nicl.2013.05.004.
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